NO20013675D0 - 2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer - Google Patents

2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer

Info

Publication number: NO20013675D0
Authority: NO; Norway
Prior art keywords: benzodiazepine; tetrahydro; hydroxamic acid; matrix metalloproteinase; metalloproteinase inhibitors
Prior art date: 1999-01-27

Application number

NO20013675A

Other languages

English (en)

Other versions

NO20013675L (no

Inventor

Jay Donald Albright

Efren Guillermo Delos Santos

Jeremy Ian Levin

James Ming Chen

Original Assignee

American Cyanamid Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2001-07-26

Publication date

2001-07-26

2001-07-26 Application filed by American Cyanamid Co filed Critical American Cyanamid Co

2001-07-26 Publication of NO20013675D0 publication Critical patent/NO20013675D0/no

2001-09-21 Publication of NO20013675L publication Critical patent/NO20013675L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)

NO20013675A 1999-01-27 2001-07-26 2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer NO20013675L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US23908099A	1999-01-27	1999-01-27
PCT/US2000/001991 WO2000044730A1 (en)	1999-01-27	2000-01-27	2,3,4,5-tetrahydro-1h-[1,4]benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20013675D0 true NO20013675D0 (no)	2001-07-26
NO20013675L NO20013675L (no)	2001-09-21

Family

ID=22900512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20013675A NO20013675L (no)	1999-01-27	2001-07-26	2,3,4,5-tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinase-inhibitorer

Country Status (25)

Country	Link
EP (1)	EP1147095B1 (no)
JP (1)	JP2002535392A (no)
KR (1)	KR20010101730A (no)
CN (1)	CN1197849C (no)
AR (1)	AR022423A1 (no)
AT (1)	ATE273288T1 (no)
AU (1)	AU767039B2 (no)
BG (1)	BG105736A (no)
BR (1)	BR0007759A (no)
CA (1)	CA2356267A1 (no)
CZ (1)	CZ20012637A3 (no)
DE (1)	DE60012883T2 (no)
EA (1)	EA200100809A1 (no)
ES (1)	ES2223470T3 (no)
HU (1)	HUP0105302A3 (no)
ID (1)	ID29046A (no)
IL (1)	IL144168A0 (no)
NO (1)	NO20013675L (no)
NZ (1)	NZ511885A (no)
PL (1)	PL349025A1 (no)
PT (1)	PT1147095E (no)
SK (1)	SK10422001A3 (no)
TR (1)	TR200102131T2 (no)
WO (1)	WO2000044730A1 (no)
ZA (1)	ZA200104321B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2357110A1 (en) *	2001-04-11	2002-10-11	American Cyanamid Company	Method for the treatment of polycystic kidney disease
US20070122353A1 (en)	2001-05-24	2007-05-31	Hale Ron L	Drug condensation aerosols and kits
US20030051728A1 (en)	2001-06-05	2003-03-20	Lloyd Peter M.	Method and device for delivering a physiologically active compound
WO2003016248A2 (en)	2001-08-17	2003-02-27	Bristol-Myers Squibb Company Patent Department	Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
CN1610661A (zh)	2001-11-01	2005-04-27	惠氏控股公司	用作基质金属蛋白酶和tace的抑制剂的丙二烯芳基磺酰胺异羟肟酸
US7488754B2 (en)	2002-04-05	2009-02-10	Wyeth	Method for the treatment of polycystic kidney disease
AU2003253176A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003304456A1 (en)	2002-12-23	2005-03-16	Wyeth Holdings Corporation	Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1625333A1 (en)	2003-05-21	2006-02-15	Alexza Pharmaceuticals, Inc.	Self-contained heating unit and drug-supply unit employing same
WO2006008303A1 (en) *	2004-07-21	2006-01-26	Applied Research Systems Ars Holding N.V.	Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof
EP1865001A1 (en) *	2006-06-08	2007-12-12	Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh	Specific protease inhibitors and their use in cancer therapy
EP2041181B1 (en) *	2006-06-08	2011-05-18	Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Specific protease inhibitors and their use in cancer therapy
ES2594867T3 (es)	2007-03-09	2016-12-23	Alexza Pharmaceuticals, Inc.	Unidad de calentamiento para usar en un dispositivo de administración de fármaco
FR2950057B1 (fr)	2009-09-17	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2950056B1 (fr)	2009-09-17	2011-08-26	Galderma Res & Dev	Nouveaux composes benzene-carboxylamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
KR101822444B1 (ko)	2010-07-08	2018-01-26	가켄 세이야쿠 가부시키가이샤	N-히드록시포름아미드 유도체 및 그를 함유하는 의약
RU2578607C2 (ru) *	2010-09-17	2016-03-27	Дзе Юниверсити Оф Токио	Композиция для поддержания функции тромбоцитов
CA3115038A1 (en)	2018-10-04	2020-04-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Egfr inhibitors for treating keratodermas
WO2021055817A1 (en) *	2019-09-19	2021-03-25	New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery	Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5455258A (en) *	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
EP0821671B1 (en) *	1995-04-20	2000-12-27	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
PL186869B1 (pl) *	1995-11-13	2004-03-31	Hoechst Ag	Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie
IL124559A (en) *	1995-12-08	2004-07-25	Agouron Pharma	Inhibitors of metalloproteinases, pharmaceutical preparations containing them and their use
US5753653A (en) *	1995-12-08	1998-05-19	Agouron Pharmaceuticals, Inc.	Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998008822A1 (en) *	1996-08-28	1998-03-05	The Procter & Gamble Company	1,3-diheterocyclic metalloprotease inhibitors
EP0923561B1 (en) *	1996-08-28	2002-10-23	The Procter & Gamble Company	Heterocyclic metalloprotease inhibitors
CN1228773A (zh) *	1996-08-28	1999-09-15	普罗克特和甘保尔公司	杂环金属蛋白酶抑制剂
JP2002501056A (ja) *	1998-01-27	2002-01-15	アメリカン・サイアナミド・カンパニー	マトリクス金属プロテイナーゼ阻害薬としての２，３，４，５−テトラヒドロ−１ｈ−［１，４］−ベンゾジアゼピン−３−ヒドロキサム酸

2000
- 2000-01-26 AR ARP000100323A patent/AR022423A1/es not_active Application Discontinuation
- 2000-01-27 AT AT00909990T patent/ATE273288T1/de not_active IP Right Cessation
- 2000-01-27 NZ NZ511885A patent/NZ511885A/xx unknown
- 2000-01-27 ES ES00909990T patent/ES2223470T3/es not_active Expired - Lifetime
- 2000-01-27 CZ CZ20012637A patent/CZ20012637A3/cs unknown
- 2000-01-27 IL IL14416800A patent/IL144168A0/xx unknown
- 2000-01-27 TR TR2001/02131T patent/TR200102131T2/xx unknown
- 2000-01-27 JP JP2000595986A patent/JP2002535392A/ja active Pending
- 2000-01-27 BR BR0007759-3A patent/BR0007759A/pt not_active IP Right Cessation
- 2000-01-27 WO PCT/US2000/001991 patent/WO2000044730A1/en active IP Right Grant
- 2000-01-27 PT PT00909990T patent/PT1147095E/pt unknown
- 2000-01-27 EP EP00909990A patent/EP1147095B1/en not_active Expired - Lifetime
- 2000-01-27 DE DE60012883T patent/DE60012883T2/de not_active Expired - Fee Related
- 2000-01-27 SK SK1042-2001A patent/SK10422001A3/sk unknown
- 2000-01-27 CN CNB008031355A patent/CN1197849C/zh not_active Expired - Fee Related
- 2000-01-27 ID IDW00200101465A patent/ID29046A/id unknown
- 2000-01-27 PL PL00349025A patent/PL349025A1/xx not_active Application Discontinuation
- 2000-01-27 HU HU0105302A patent/HUP0105302A3/hu unknown
- 2000-01-27 CA CA002356267A patent/CA2356267A1/en not_active Abandoned
- 2000-01-27 KR KR1020017009430A patent/KR20010101730A/ko not_active Application Discontinuation
- 2000-01-27 EA EA200100809A patent/EA200100809A1/ru unknown
- 2000-01-27 AU AU32160/00A patent/AU767039B2/en not_active Ceased
2001
- 2001-05-25 ZA ZA200104321A patent/ZA200104321B/en unknown
- 2001-07-26 NO NO20013675A patent/NO20013675L/no not_active Application Discontinuation
- 2001-07-26 BG BG105736A patent/BG105736A/xx unknown

Also Published As

Publication number	Publication date
KR20010101730A (ko)	2001-11-14
EP1147095A1 (en)	2001-10-24
AU767039B2 (en)	2003-10-30
HUP0105302A2 (hu)	2002-07-29
ZA200104321B (en)	2002-08-26
DE60012883T2 (de)	2005-08-25
PT1147095E (pt)	2004-12-31
CN1337952A (zh)	2002-02-27
IL144168A0 (en)	2002-05-23
NO20013675L (no)	2001-09-21
BG105736A (en)	2002-05-31
EP1147095B1 (en)	2004-08-11
CA2356267A1 (en)	2000-08-03
CZ20012637A3 (cs)	2002-04-17
ES2223470T3 (es)	2005-03-01
WO2000044730A1 (en)	2000-08-03
DE60012883D1 (de)	2004-09-16
AU3216000A (en)	2000-08-18
ATE273288T1 (de)	2004-08-15
ID29046A (id)	2001-07-26
BR0007759A (pt)	2001-11-13
EA200100809A1 (ru)	2002-02-28
NZ511885A (en)	2003-06-30
SK10422001A3 (sk)	2002-09-10
JP2002535392A (ja)	2002-10-22
AR022423A1 (es)	2002-09-04
TR200102131T2 (tr)	2001-12-21
PL349025A1 (en)	2002-07-01
HUP0105302A3 (en)	2002-09-30
CN1197849C (zh)	2005-04-20

Publication	Publication Date	Title
EE200000720A (et)	2002-04-15	Uus 3-arüül-2-hüdroksüpropaanhappe derivaat (I)
NO20013675D0 (no)	2001-07-26	2,3,4,5-Tetrahydro-1H-[1,4)benzodiazepin-3-hydroksamsyre som matriks-metalloproteinaseinhibitorer
DK1244647T3 (da)	2006-09-25	Quinzolinderivater som VIGF-inhibitorer
NO20002217D0 (no)	2000-04-28	Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
DK1036062T3 (da)	2004-04-05	Hydroxamsyrederivater som matrix metalloprotease (MMP) inhibitorer
DK1114032T3 (da)	2004-08-16	4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
DK1460066T3 (da)	2009-11-02	Piperazinforbindelse som tachykinin-inhibitorer
NO20015065L (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
EE200000717A (et)	2001-08-15	Uus 3-arüül-2-hüdroksüpropaanhappe derivaat III
DK1210326T3 (da)	2004-06-21	Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
NO20021407L (no)	2002-03-21	Bifenylderivater anvendt som NHE-3-inhibitorer
DE60043730D1 (de)	2010-03-11	Arylsulfonamid-substituierte hydroxamsäure-derivate
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
NO991994D0 (no)	1999-04-27	Substituerte 4-bifenyl-4-hydroksysm°rsyrederivater som matriks-metalloproteaseinhibitorer
NO20013853L (no)	2001-10-09	Heteroarylamidiner, metylamidiner og guanidiner som proteaseinhibitorer
ATE309220T1 (de)	2005-11-15	Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
NO20003828D0 (no)	2000-07-26	2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
DK1047665T3 (da)	2004-02-02	Matrix metalloprotease inhibitorer
PL357084A1 (en)	2004-07-12	Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors
DK1487802T3 (da)	2011-04-04	2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer
DK1147095T3 (da)	2004-11-15	2,3,4,5-Tetrahydro-1H-[1,4]benzodiazepin-3-hydroxamsyrer som matrixmetalloproteinaseinhibitorer
DK1380585T3 (da)	2005-03-07	Pyrazolopyridinon som mellemprodukt
IT1311642B1 (it)	2002-03-14	Struttura di calzatura,

Legal Events

Date	Code	Title	Description
2005-09-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application